Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept: A US Real-World Evidence Study

Inclusion Criteria for Patient Population:

1. All aflibercept injections identified by the Healthcare Common Procedure Coding System (HCPCS) or National Drug Code (NDC) from January 1, 2017, to February 29, 2024, as recorded in the Komodo close claims database.

Key Exclusion Criteria:

1. Aflibercept injections with unspecified laterality will be excluded

2. Aflibercept injections from individuals aged <18 years or those with unknown age onthe injection date will be excluded

3. Patient-eyes with a diagnosis of RV in the same eye as the aflibercept injection orwith unspecified laterality within 12 months (365 days) prior to index date (inclusive), as defined in the protocol

4. Patient-eyes that do not meet the continuous enrollment requirement will be excluded

5. Aflibercept injections will be excluded if there is ≥1 other anti-VEGF injectionadministered on the same date

NOTE: Other Protocol-defined Inclusion/Exclusion Criteria Apply